ClinicalTrials.gg
Status unknownNCT00199277Updated Sep 20, 2005

Iron Therapy in Colo-Rectal Neoplasm and Iron Deficiency Anemia: Intravenous Iron Sucrose Versus Oral Ferrous Sulphate.

A Phase 4 interventional study of i.v. iron sucrose and Oral iron in Colorectal Neoplasm and Iron Deficiency Anemia, sponsored by J. Uriach and Company. Status unknown at 5 sites in Spain. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2005-09-20.

Sponsored by J. Uriach and Company · Phase 4, Interventional, and Treatment

The sponsor has not verified this record recently (last verified Sep 2005), so the status shown — last known as Not yet recruiting — may be out of date.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
150
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 461 studies in Colorectal Neoplasms with a site in Spain — 96 open to participants now, 149 under way, 18 of them phase 3. Colorectal Neoplasms · Spain.

Enrollment
220th of 404
150 · median 168
Phase 4
7 of 461
1 open now
Registered
18th of 461
by date

Among the 461 studies in Colorectal Neoplasms with a site in Spain, this one is the 220th largest by enrollment of the 404 interventional ones that give a count, is one of 7 in phase 4, and was the 18th registered.

Colorectal Neoplasms

6,548 studies on the registry are indexed under Colorectal Neoplasms; 1,664 are open to participants now.

Browse Colorectal Neoplasms studies →

Open to participants now

96 of the 461 studies in Colorectal Neoplasms with a site in Spain are open now. Recruiting first, the newest first:

91 more — sign in →

All 96 open studies →

A study can be open while its sites in Spain have not opened yet or have stopped. Only those recruiting at a site in Spain →

Who these studies take

Of the 1,179 Colorectal Neoplasms studies recruiting now, 762 (65%) set no upper age limit and 264 (22%) stop at 75 or younger; 48 take children under 18; 123 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 461 studies in Colorectal Neoplasms with a site in Spain, or all of them as a file.
02

Study summary

The main objective of this study is to evaluate the efficacy of intravenous iron sucrose in increasing preoperative haemoglobin values in patients with colo-rectal neoplasm and iron deficiency anemia, compared to the standard treatment with oral iron. It will also determine whether intravenous iron sucrose administration improves outcomes such as postoperative haemoglobin values, serum ferritin values, transfusional needs, postoperative complications, or length of hospital stay.

Read the detailed description

Most patients with colorectal neoplasm have iron deficiency, which can be triggered in the pre-operative period by a decrease of iron intake and the bleeding in the site of neoplasm.

In the postoperative period, iron deficiency can be aggravated by surgical bleeding.

Iron plays a leading rol in haemoglobin production, cell mitosis and immune system. Animal experimentation has shown that induced iron deficiency and mild anemia lead to postoperative mortality and lactacidemia in a model of peritonitis.

Moreover, anemia is the main risk factor to require intra and postoperative blood transfusions, and iron deficiency and anemia are associated to a larger number of postoperative complications (infections and longer hospital stay).

Oral iron therapy is the standard treatment in patients with preoperative iron deficiency, but iron levels inside red cells may not reach normality in time before surgery, and it can not be resumed until the patient can start again oral feeding.

In these patients, any increase in preoperative haemoglobin decreases the risk to need a blood transfusion during or after surgery.

This trial will compare standard oral iron and intravenous iron.

03

Conditions studied

  • Colorectal Neoplasm
  • Iron Deficiency Anemia
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Non-recurrent colorectal neoplasm, surgically resectable
  • Anemia

Exclusion criteria

Exclusion Criteria:

  • Severe renal impairment
  • High anesthetic risk
05

Study design

Phase
Phase 4
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
150 participants

Interventions

06

What researchers measure

Primary outcomes

  1. Preoperative variations in hemoglobin.

Secondary outcomes

  1. Postoperative variations in hemoglobin.

  2. Blood transfusion needs (pre, intra and postoperative)

  3. Postoperative complications:

  4. - Pulmonary thromboembolism

  5. - Infections

  6. - Reintervention

  7. - Death

  8. Length of hospital stay

07

Study locations

5 sites
  • Hospital Universitari Germans Trias i Pujol
    Badalona, Barcelona, Spain
    • Marta Piñol Pascual, MD · Contact
    • Marta Piñol Pascual, MD · Principal investigator
  • Hospital Comarcal Sant Jaume de Calella.
    Calella, Barcelona, Spain
    • Dolors Vela Payán, MD · Contact
    • Dolors Vela Payán, MD · Principal investigator
  • Fundació Hospital Asil de Granollers
    Granollers, Barcelona, Spain
    • Ramón López Ferré, MD · Contact
    • Ramón López Ferré, MD · Principal investigator
  • Consorci Sanitari del Maresme
    Mataró, Barcelona, Spain
    • Alba Bosch Llobet, MD · Contact
    • Alba Bosch Llobet, MD · Principal investigator
  • Hospital Miguel Servet
    Zaragoza, Spain
    • José Antonio García-Erce, MD · Contact
    • José Antonio García-Erce, MD · Principal investigator
08

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Sep 20, 2005, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT00199277
Lead sponsor
J. Uriach and Company
First posted
Sep 20, 2005
Last update
Sep 20, 2005

Study contacts

Pere Poch Martí, MD
study chair · Fundació Hospital-Asil de Granollers (Barcelona, Spain)
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is status unknown, as verified in Sep 2005. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Iron

Start the discussion